On the public citation graph
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
0 signed · 1058 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2016.11708openalex-snapshot
Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
inferredcites →https://doi.org/10.1001/jama.2017.7115openalex-snapshot
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes
inferredcites →https://doi.org/10.1001/jama.2017.7117openalex-snapshot
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.1001/jama.287.19.2563openalex-snapshot
Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus
inferredcites →https://doi.org/10.1001/jama.289.17.2254openalex-snapshot
Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1001/jamainternmed.2014.2894openalex-snapshot
Effect of Patients’ Risks and Preferences on Health Gains With Plasma Glucose Level Lowering in Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1002/14651858.cd005613.pub3openalex-snapshot
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
inferredcites →https://doi.org/10.1002/cpt.1307openalex-snapshot
A Model‐Based Meta‐Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses
inferredcites →https://doi.org/10.1002/dmrr.2983openalex-snapshot
Effect of metformin on glycaemic control in patients with type 1 diabetes: A meta‐analysis of randomized controlled trials
inferredcites →https://doi.org/10.1007/s00125-005-0132-0openalex-snapshot
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study
inferredcites →https://doi.org/10.1007/s13300-017-0282-3openalex-snapshot
Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.1016/j.diabres.2008.04.007openalex-snapshot
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
inferredcites →https://doi.org/10.1016/j.diabres.2016.10.022openalex-snapshot
Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy
inferredcites →https://doi.org/10.1016/j.diabres.2018.06.016openalex-snapshot
Cost-related medication non-adherence among U.S. adults with diabetes
inferredcites →https://doi.org/10.1016/j.ecl.2012.03.001openalex-snapshot
Insulin Therapy and Hypoglycemia
inferredcites →https://doi.org/10.1016/j.jdiacomp.2017.11.001openalex-snapshot
Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3 year trial
inferredcites →https://doi.org/10.1016/j.mayocp.2014.12.014openalex-snapshot
Safety and Efficacy of Insulin Therapy Delivered via a 4mm Pen Needle in Obese Patients With Diabetes
inferredcites →https://doi.org/10.1016/j.mayocp.2016.06.010openalex-snapshot
New Insulin Delivery Recommendations
inferredcites →https://doi.org/10.1016/s0140-6736(10)60406-0openalex-snapshot
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
inferredcites →https://doi.org/10.1016/s0140-6736(14)61335-0openalex-snapshot
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/s0140-6736(18)31947-0openalex-snapshot
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
inferredcites →https://doi.org/10.1016/s0140-6736(19)31271-1openalex-snapshot
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
inferredcites →https://doi.org/10.1016/s0140-6736(19)32131-2openalex-snapshot
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
inferredcites →https://doi.org/10.1016/s2213-8587(13)70090-1openalex-snapshot
Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial
inferredcites →https://doi.org/10.1016/s2213-8587(13)70144-xopenalex-snapshot
Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/s2213-8587(17)30085-2openalex-snapshot
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
inferredcites →https://doi.org/10.1016/s2213-8587(17)30194-8openalex-snapshot
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
inferredcites →https://doi.org/10.1016/s2213-8587(17)30308-xopenalex-snapshot
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
inferredcites →https://doi.org/10.1016/s2213-8587(19)30184-6openalex-snapshot
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
inferredcites →https://doi.org/10.1056/nejmoa052187openalex-snapshot
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa0806470openalex-snapshot
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1303576openalex-snapshot
Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
inferredcites →https://doi.org/10.1056/nejmoa1615692openalex-snapshot
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
inferredcites →https://doi.org/10.1089/dia.2016.0421openalex-snapshot
Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
inferredcites →https://doi.org/10.1089/dia.2018.0200openalex-snapshot
Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
inferredcites →https://doi.org/10.1097/mlr.0000000000000565openalex-snapshot
Social Determinants of Health, Cost-related Nonadherence, and Cost-reducing Behaviors Among Adults With Diabetes
inferredcites →https://doi.org/10.1111/1753-0407.12060openalex-snapshot
Meta‐analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus (在基础—餐时糖尿病治疗方案中使用门冬胰岛素与使用常规人胰岛素对照研究的Meta分析)
inferredcites →https://doi.org/10.1111/dme.12303openalex-snapshot
Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial
inferredcites →https://doi.org/10.1111/dom.12233openalex-snapshot
Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta‐analysis
inferredcites →https://doi.org/10.1111/dom.12417openalex-snapshot
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E fficacy and D urability of I nitial C ombination T herapy for T ype 2 D iabetes ( EDICT ): a randomized trial
inferredcites →https://doi.org/10.1111/dom.12438openalex-snapshot
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)
inferredcites →https://doi.org/10.1111/dom.12472openalex-snapshot
One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal‐time insulin: the EDITION 1 12‐month randomized trial, including 6‐month extension
inferredcites →https://doi.org/10.1111/dom.12532openalex-snapshot
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension
inferredcites →https://doi.org/10.1111/dom.12618openalex-snapshot
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial ( EDITION JP 2)
inferredcites →https://doi.org/10.1111/dom.12804openalex-snapshot
A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
inferredcites →https://doi.org/10.1111/dom.12805openalex-snapshot
Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis
inferredcites →https://doi.org/10.1111/dom.14100openalex-snapshot
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study
inferredcites →https://doi.org/10.1111/j.1463-1326.2008.00934.xopenalex-snapshot
Short‐acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta‐analysis
inferredcites →https://doi.org/10.1111/j.1463-1326.2009.01060.xopenalex-snapshot
Patient‐directed titration for achieving glycaemic goals using a once‐daily basal insulin analogue: an assessment of two different fasting plasma glucose targets ‐ the TITRATE TM study
inferredcites →https://doi.org/10.1111/j.1464-5491.2004.01319.xopenalex-snapshot
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial
inferredcites →https://doi.org/10.1111/j.1464-5491.2007.02407.xopenalex-snapshot
Long‐term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat‐to‐target basal–bolus regimen with insulin aspart at meals: a 2‐year, randomized, controlled trial
inferredcites →https://doi.org/10.1111/j.1742-1241.2012.02911.xopenalex-snapshot
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
inferredcites →https://doi.org/10.1136/bmj.g5459openalex-snapshot
Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis
inferredcites →https://doi.org/10.1177/193229681300700617openalex-snapshot
The Evidence Base for Diabetes Technology: Appropriate and Inappropriate Meta-Analysis
inferredcites →https://doi.org/10.1210/jc.2015-3754openalex-snapshot
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study
inferredcites →https://doi.org/10.1503/cmaj.081041openalex-snapshot
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
inferredcites →https://doi.org/10.20945/2359-3997000000045openalex-snapshot
Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis
inferredcites →https://doi.org/10.2147/dmso.s130834openalex-snapshot
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
inferredcites →https://doi.org/10.2337/cd19-0061openalex-snapshot
Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
inferredcites →https://doi.org/10.2337/db06-0653openalex-snapshot
The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
inferredcites →https://doi.org/10.2337/dc05-1365openalex-snapshot
A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc06-0042openalex-snapshot
A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes
inferredcites →https://doi.org/10.2337/dc09-2011openalex-snapshot
Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc12-1205openalex-snapshot
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc12-1333openalex-snapshot
Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
inferredcites →https://doi.org/10.2337/dc14-0649openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc14-0876openalex-snapshot
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc14-0990openalex-snapshot
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
inferredcites →https://doi.org/10.2337/dc14-1625openalex-snapshot
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
inferredcites →https://doi.org/10.2337/dc14-3053openalex-snapshot
Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis
inferredcites →https://doi.org/10.2337/dc15-0075openalex-snapshot
Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial
inferredcites →https://doi.org/10.2337/dc15-0100openalex-snapshot
Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era
inferredcites →https://doi.org/10.2337/dc15-0249openalex-snapshot
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
inferredcites →https://doi.org/10.2337/dc15-2399openalex-snapshot
Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population
inferredcites →https://doi.org/10.2337/dc16-1771openalex-snapshot
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)
inferredcites →https://doi.org/10.2337/dc16-1957openalex-snapshot
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
inferredcites →https://doi.org/10.2337/dc18-1749openalex-snapshot
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
inferredcites →https://doi.org/10.2337/dci18-0012openalex-snapshot
The Cost of Diabetes Care—An Elephant in the Room
inferredcites →https://doi.org/10.2337/dci18-0019openalex-snapshot
Insulin Access and Affordability Working Group: Conclusions and Recommendations
inferredcites →https://doi.org/10.2337/dci18-0033openalex-snapshot
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferredcites →https://doi.org/10.2337/dci19-0066openalex-snapshot
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferredcites →https://doi.org/10.2337/dcs15-3007openalex-snapshot
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
inferredcites →https://doi.org/10.4158/ep09117.orropenalex-snapshot
Safe and Simple Emergency Department Discharge Therapy for Patients with Type 2 Diabetes Mellitus and Severe Hyperglycemia
inferredcites →https://doi.org/10.4158/ep15959.oropenalex-snapshot
Effect of Total Daily Dose on Efficacy, Dosing, and Safety of 2 Dose Titration Regimens of Human Regular U-500 Insulin in Severely Insulin-Resistant Patients with Type 2 Diabetes
inferredcites →https://doi.org/10.7326/0003-4819-154-9-201105030-00336openalex-snapshot
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
inferredcites →https://doi.org/10.7326/0003-4819-157-5-201209040-00508openalex-snapshot
Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus
inferredcites →https://doi.org/10.7326/m15-2650openalex-snapshot
Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
inferredcites →https://doi.org/10.7326/m20-0864openalex-snapshot
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.3859307openalex-extracted
Advantages of Metformin Therapy for the Prevention and Mitigation of Diabetic Foot Ulcer in Patients With Diabetic Kidney Disease: A Real-Word Evidence From Large-Scale Cohort
inferred← citeshttps://doi.org/10.1001/jama.2021.12559openalex-snapshot
New USPSTF Recommendations for Screening for Prediabetes and Type 2 Diabetes
inferred← citeshttps://doi.org/10.1001/jamainternmed.2021.2487openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas
inferred← citeshttps://doi.org/10.1001/jamainternmed.2023.6663openalex-snapshot
Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.28782openalex-snapshot
Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.30762openalex-snapshot
Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.1169openalex-snapshot
Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.35995openalex-snapshot
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.40117openalex-snapshot
Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.41505openalex-snapshot
Exploration of Residual Confounding in Analyses of Associations of Metformin Use and Outcomes in Adults With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.53562openalex-snapshot
Continuity of Medication Use by US Adults With Diabetes, 2005-2019
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.0427openalex-snapshot
Representation of Patients With Chronic Kidney Disease in Clinical Trials of Cardiovascular Disease Medications
inferred← citeshttps://doi.org/10.1002/9781119697473.ch30openalex-snapshot
Biomarkers and Precision Medicine in Diabetes
inferred← citeshttps://doi.org/10.1002/9781119697473.ch36openalex-snapshot
Non‐insulin Parenteral Therapies
inferred← citeshttps://doi.org/10.1002/9781119785033.ch3openalex-snapshot
Sulfonylureas and Meglitinides
inferred← citeshttps://doi.org/10.1002/alz.14048openalex-snapshot
Heterogeneous treatment effects of sodium‐glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population‐based cohort study
inferred← citeshttps://doi.org/10.1002/brb3.71616openalex-snapshot
Burden of Diabetes as a Contributing Cause in Dementia Mortality Among Older Adults in the United States, 1999–2020
inferred← citeshttps://doi.org/10.1002/clc.23853openalex-snapshot
Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial
inferred← citeshttps://doi.org/10.1002/clc.23948openalex-snapshot
Knowledge of HbA1c and LDL‐C treatment goals, subjective level of disease‐related information and information needs in patients with atherosclerotic cardiovascular disease
inferred← citeshttps://doi.org/10.1002/cpdd.1187openalex-snapshot
A Single‐dose, Two‐Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects
inferred← citeshttps://doi.org/10.1002/cpdd.1310openalex-snapshot
Pharmacokinetic Comparison Between a Fixed‐Dose Combination of Empagliflozin L‐Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects
inferred← citeshttps://doi.org/10.1002/cpdd.1528openalex-snapshot
Comparative Bioequivalence Study of 2 Fixed‐Dose Combinations of Vildagliptin and Metformin at a Tablet Strength of 50/1000 mg in Moroccan Volunteers
inferred← citeshttps://doi.org/10.1002/cpt.2975openalex-snapshot
Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and DPP ‐4 Inhibitors: Population‐Based Cohort Study
inferred← citeshttps://doi.org/10.1002/dmrr.3503openalex-snapshot
The new dual gastric inhibitory peptide/glucagon‐like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
inferred← citeshttps://doi.org/10.1002/dmrr.3535openalex-snapshot
Diabetes mellitus and multiple myeloma; common features of two distinct entities
inferred← citeshttps://doi.org/10.1002/dmrr.3615openalex-snapshot
Real world evidence of clinical predictors of glycaemic response to glucose‐lowering drugs among Chinese with type 2 diabetes
inferred← citeshttps://doi.org/10.1002/dmrr.3830openalex-snapshot
The long‐term effect of bariatric/metabolic surgery versus pharmacologic therapy in type 2 diabetes mellitus patients: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/edm2.319openalex-snapshot
The use of glucose‐lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States
inferred← citeshttps://doi.org/10.1002/edm2.330openalex-snapshot
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
inferred← citeshttps://doi.org/10.1002/ehf2.14213openalex-snapshot
Meta-Analysed Numbers Needed to Treat of Novel Antidiabetic Drugs for Cardiovascular Outcomes
inferred← citeshttps://doi.org/10.1002/fsn3.70699openalex-snapshot
Gallic Acid and Vitamin C Mitigate Histopathological Changes in the Retina by Attenuating Dyslipidemia and Mitigating Oxidative Stress, Inflammation, and Apoptosis in the Eyes of Type 2 Diabetic Rats Induced With Fructose/Streptozotocin
inferred← citeshttps://doi.org/10.1002/hep.31886openalex-snapshot
The Glucagon‐Like Peptide‐1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.1002/hep.32742openalex-snapshot
Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial
inferred← citeshttps://doi.org/10.1002/hep4.1876openalex-snapshot
Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management
inferred← citeshttps://doi.org/10.1002/jac5.1544openalex-snapshot
Comparative performance of annual wellness visits between pharmacists and physicians at primary care clinics
inferred← citeshttps://doi.org/10.1002/jac5.1626openalex-snapshot
Retrospective, cohort review of pharmacists' impact on disparities in care in the management of type 2 diabetes with glucagon‐like peptide‐1 agonists and sodium glucose co‐transporter 2 inhibitors
inferred← citeshttps://doi.org/10.1002/oby.24172openalex-snapshot
G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials
inferred← citeshttps://doi.org/10.1002/pds.5665openalex-snapshot
Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data
inferred← citeshttps://doi.org/10.1002/phar.2527openalex-snapshot
Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction
inferred← citeshttps://doi.org/10.1002/phar.2648openalex-snapshot
Clinical Impact of GLP‐1 receptor agonists in veterans receiving basal‐bolus insulin
inferred← citeshttps://doi.org/10.1002/pmrj.12859openalex-snapshot
Multi‐disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post‐acute sequelae of SARS‐CoV ‐2 infection ( PASC )
inferred← citeshttps://doi.org/10.1002/sfp2.1006openalex-snapshot
Differences and similarities of albumins from japonica rice bran, japonica, indica, and javanica rice endosperm in the suppressive effect of postprandial blood glucose elevation
inferred← citeshttps://doi.org/10.1007/978-3-030-86020-2_2openalex-snapshot
Diabetes and Kidney Disease: A Review of the Clinical Practice Guidelines
inferred← citeshttps://doi.org/10.1007/978-3-030-89243-2_19openalex-snapshot
Long-Term Maternal Complications
inferred← citeshttps://doi.org/10.1007/978-3-030-98927-9_1openalex-snapshot
Precision Medicine Approaches for Management of Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-031-06231-5_19openalex-snapshot
Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome
inferred← citeshttps://doi.org/10.1007/978-3-031-13009-0_28openalex-snapshot
Control of Blood Glucose and Cardiovascular Risk Profile
inferred← citeshttps://doi.org/10.1007/978-3-031-13177-6_34openalex-snapshot
Insulin Treatment of Diabetes Mellitus-Tight vs. Conventional Control
inferred← citeshttps://doi.org/10.1007/978-3-031-13177-6_37openalex-snapshot
Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual
inferred← citeshttps://doi.org/10.1007/978-3-031-20193-6_18openalex-snapshot
Medications to Avoid When Treating Heart Failure
inferred← citeshttps://doi.org/10.1007/978-3-031-25519-9_19openalex-snapshot
Diabetes Management in the United States
inferred← citeshttps://doi.org/10.1007/978-3-031-25519-9_34openalex-snapshot
The “Old” Oral Antidiabetics
inferred← citeshttps://doi.org/10.1007/978-3-032-08246-6_7openalex-snapshot
AI Systems Real-Time Focused Screening of Diabetic Retinopathy Using Deep Learning
inferred← citeshttps://doi.org/10.1007/978-3-032-09817-7_8openalex-snapshot
Everyday Practice in Blood Glucose Management During Perioperative Cardiac Surgery
inferred← citeshttps://doi.org/10.1007/978-3-319-31420-4_19-2openalex-snapshot
Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome
inferred← citeshttps://doi.org/10.1007/978-981-16-5123-6_20openalex-snapshot
Long-Term Glycemic Control for Stroke Survivors
inferred← citeshttps://doi.org/10.1007/978-981-97-7568-2_1openalex-snapshot
The History of the Development of SGLT2 Inhibitors for the Treatment of Diabetes: From Biology to Chemistry
inferred← citeshttps://doi.org/10.1007/978-981-97-7568-2_6openalex-snapshot
Role of Therapeutic Potential, Contemporary Management, Unmet needs of SGLT2 Inhibitors in Congestive Heart Failure
inferred← citeshttps://doi.org/10.1007/s00125-022-05715-4openalex-snapshot
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00125-023-05950-3openalex-snapshot
Health and economic impact of improved glucose, blood pressure and lipid control among German adults with type 2 diabetes: a modelling study
inferred← citeshttps://doi.org/10.1007/s00280-025-04822-4openalex-snapshot
Non-oncologic to oncologic drug: A systematic review of drug repurposing in cancer
inferred← citeshttps://doi.org/10.1007/s00395-024-01059-9openalex-snapshot
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
inferred← citeshttps://doi.org/10.1007/s00467-021-05347-7openalex-snapshot
Diabetic kidney disease in children and adolescents: an update
inferred← citeshttps://doi.org/10.1007/s00592-023-02045-8openalex-snapshot
Prediction of complications in health economic models of type 2 diabetes: a review of methods used
inferred← citeshttps://doi.org/10.1007/s00772-021-00855-0openalex-snapshot
Empfehlungen zur konservativen Therapie und Sekundärprävention der peripheren arteriellen Verschlusskrankheit (PAVK): Eine evidenzbasierte Informationsbroschüre für Betroffene
inferred← citeshttps://doi.org/10.1007/s00772-024-01086-9openalex-snapshot
Behandlung der chronischen peripheren arteriellen Verschlusskrankheit (pAVK)
inferred← citeshttps://doi.org/10.1007/s00774-022-01372-0openalex-snapshot
Hip and vertebral fracture risk after initiating antidiabetic drugs in Japanese elderly: a nationwide study
inferred← citeshttps://doi.org/10.1007/s10103-021-03434-7openalex-snapshot
Effects of photobiomodulation on glucose homeostasis and morphometric parameters in pancreatic islets of diabetic mice
inferred← citeshttps://doi.org/10.1007/s10389-022-01769-1openalex-snapshot
Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1007/s10549-022-06798-8openalex-snapshot
Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
inferred← citeshttps://doi.org/10.1007/s10787-025-01750-wopenalex-snapshot
Dapagliflozin targets the crosstalk between apoptosis, autophagy, and Hedgehog signaling pathways through AMPK activation in the adjuvant-induced arthritic rat model
inferred← citeshttps://doi.org/10.1007/s10961-026-10375-2openalex-snapshot
From approval to routine use: the two-stage technology transfer of new drugs in U.S. clinical practice
inferred← citeshttps://doi.org/10.1007/s11010-022-04374-8openalex-snapshot
Identification and management of GCK-MODY complicating pregnancy in Chinese patients with gestational diabetes
inferred← citeshttps://doi.org/10.1007/s11096-022-01464-xopenalex-snapshot
A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country
inferred← citeshttps://doi.org/10.1007/s11154-021-09675-9openalex-snapshot
Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
inferred← citeshttps://doi.org/10.1007/s11428-023-01024-5openalex-snapshot
Formel zur Abschätzung der Dosierung bei Neueinstellung auf Insulin
inferred← citeshttps://doi.org/10.1007/s11517-022-02602-3openalex-snapshot
Prioritizing the glucose-lowering medicines for type 2 diabetes by an extended fuzzy decision-making approach with target-based attributes
inferred← citeshttps://doi.org/10.1007/s11606-021-07157-xopenalex-snapshot
HbA1c-Triggered Endocrinology Electronic Consultation for Type 2 Diabetes Management
inferred← citeshttps://doi.org/10.1007/s11606-021-07227-0openalex-snapshot
Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1007/s11606-021-07331-1openalex-snapshot
Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System
inferred← citeshttps://doi.org/10.1007/s11606-022-07621-2openalex-snapshot
Trends in Use of High-Cost Antihyperglycemic Drugs Among US Adults with Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s11606-024-08793-9openalex-snapshot
Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study
inferred← citeshttps://doi.org/10.1007/s11845-025-03916-5openalex-snapshot
The effect of tele-nursing based motivational interviewing on self-efficacy, self-management and metabolic control parameters in individuals with type 2 diabetes: randomized controlled study
inferred← citeshttps://doi.org/10.1007/s11886-021-01546-8openalex-snapshot
Intersection Between Chronic Kidney Disease and Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/s11886-021-01591-3openalex-snapshot
Intersection Between Diabetes and Heart Failure: Is SGLT2i the “One Stone for Two Birds” Approach?
inferred← citeshttps://doi.org/10.1007/s11892-021-01407-2openalex-snapshot
Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s11892-021-01434-zopenalex-snapshot
Managing Patients Undergoing Orthopedic Surgery to Improve Glycemic Outcomes
inferred← citeshttps://doi.org/10.1007/s11892-023-01504-4openalex-snapshot
Comparative Analysis of Clinical Practice Guidelines for the Pharmacological Treatment of Type 2 Diabetes Mellitus in Latin America
inferred← citeshttps://doi.org/10.1007/s11904-022-00600-6openalex-snapshot
Metabolic Consequences of Antiretroviral Therapy
inferred← citeshttps://doi.org/10.1007/s12325-021-01921-5openalex-snapshot
Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study
inferred← citeshttps://doi.org/10.1007/s12325-021-01985-3openalex-snapshot
Individualized HbA1c Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey
inferred← citeshttps://doi.org/10.1007/s12325-021-01989-zopenalex-snapshot
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review
inferred← citeshttps://doi.org/10.1007/s12325-022-02121-5openalex-snapshot
The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study
inferred← citeshttps://doi.org/10.1007/s12325-022-02138-wopenalex-snapshot
Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM
inferred← citeshttps://doi.org/10.1007/s12325-022-02196-0openalex-snapshot
A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study
inferred← citeshttps://doi.org/10.1007/s12325-022-02366-0openalex-snapshot
Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec: A Real-World, Prospective Non-interventional Study—UPDATES Saudi Arabia
inferred← citeshttps://doi.org/10.1007/s12325-023-02442-zopenalex-snapshot
GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice
inferred← citeshttps://doi.org/10.1007/s12325-026-03592-6openalex-snapshot
Evaluating Cost-Effectiveness in Relation to the Supporting Clinical Evidence Across the Type 2 Diabetes Continuum: A Review of Metformin and SGLT2is
inferred← citeshttps://doi.org/10.1007/s12529-023-10172-3openalex-snapshot
Trends in Diabetes Medication Taking and Incidence of Depression in Patients with Type 2 Diabetes: A Retrospective Cohort Study from 2010 to 2018
inferred← citeshttps://doi.org/10.1007/s13300-021-01034-wopenalex-snapshot
Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis
inferred← citeshttps://doi.org/10.1007/s13300-021-01045-7openalex-snapshot
The “Early Treatment” Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique
inferred← citeshttps://doi.org/10.1007/s13300-021-01065-3openalex-snapshot
New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?
inferred← citeshttps://doi.org/10.1007/s13300-021-01116-9openalex-snapshot
Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
inferred← citeshttps://doi.org/10.1007/s13300-021-01165-0openalex-snapshot
Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study
inferred← citeshttps://doi.org/10.1007/s13300-021-01170-3openalex-snapshot
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
inferred← citeshttps://doi.org/10.1007/s13300-021-01180-1openalex-snapshot
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results
inferred← citeshttps://doi.org/10.1007/s13300-021-01182-zopenalex-snapshot
Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
inferred← citeshttps://doi.org/10.1007/s13300-021-01184-xopenalex-snapshot
Comparing Real-World Effectiveness of Dulaglutide and Insulin as the First Injectable for Patients with Type 2 Diabetes: An Australian Single-Site Retrospective Chart Review
inferred← citeshttps://doi.org/10.1007/s13300-021-01188-7openalex-snapshot
Are There Different Viewpoints About the Management of Type 2 Diabetes Mellitus and Comorbidities? A Multidisciplinary Spanish Qualitative Research
inferred← citeshttps://doi.org/10.1007/s13300-021-01189-6openalex-snapshot
Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)
inferred← citeshttps://doi.org/10.1007/s13300-021-01198-5openalex-snapshot
Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations
inferred← citeshttps://doi.org/10.1007/s13300-022-01218-yopenalex-snapshot
Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
inferred← citeshttps://doi.org/10.1007/s13300-022-01222-2openalex-snapshot
Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s13300-022-01225-zopenalex-snapshot
Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Who Fast During Ramadan in The Gulf Region: A Subgroup Analysis of the Real-World ORION Study
inferred← citeshttps://doi.org/10.1007/s13300-022-01226-yopenalex-snapshot
Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
inferred← citeshttps://doi.org/10.1007/s13300-022-01247-7openalex-snapshot
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
inferred← citeshttps://doi.org/10.1007/s13300-022-01262-8openalex-snapshot
Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
inferred← citeshttps://doi.org/10.1007/s13300-022-01264-6openalex-snapshot
Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain
inferred← citeshttps://doi.org/10.1007/s13300-022-01267-3openalex-snapshot
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
inferred← citeshttps://doi.org/10.1007/s13300-022-01269-1openalex-snapshot
Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
inferred← citeshttps://doi.org/10.1007/s13300-022-01270-8openalex-snapshot
Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium–Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan
inferred← citeshttps://doi.org/10.1007/s13300-022-01282-4openalex-snapshot
Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies
inferred← citeshttps://doi.org/10.1007/s13300-022-01289-xopenalex-snapshot
An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations
inferred← citeshttps://doi.org/10.1007/s13300-022-01300-5openalex-snapshot
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
inferred← citeshttps://doi.org/10.1007/s13300-022-01302-3openalex-snapshot
Sensor-Augmented Insulin Pump with Predictive Low-Glucose Suspend (PLGS): Determining Optimal Settings of Pump and Sensor in a Multicenter Cohort of Patients with Type 1 Diabetes
inferred← citeshttps://doi.org/10.1007/s13300-022-01320-1openalex-snapshot
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study
inferred← citeshttps://doi.org/10.1007/s13300-022-01358-1openalex-snapshot
Epidemiological, Social and Economic Burden of Severe Hypoglycaemia in Patients with Diabetes Mellitus in Portugal: A Structured Literature Review
inferred← citeshttps://doi.org/10.1007/s13300-023-01421-5openalex-snapshot
Multimorbidity, Polypharmacy, Severe Hypoglycemia, and Glycemic Control in Patients Using Glucose-Lowering Drugs for Type 2 Diabetes: A Retrospective Cohort Study Using Health Insurance Claims in Japan
inferred← citeshttps://doi.org/10.1007/s13300-023-01437-xopenalex-snapshot
Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study
inferred← citeshttps://doi.org/10.1007/s13300-023-01462-wopenalex-snapshot
Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial
inferred← citeshttps://doi.org/10.1007/s13300-024-01604-8openalex-snapshot
The Efficacy and Safety of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors in Real-World Clinical Practice: Potential Cautionary Use in Elderly Patients with Type 2 Diabetes (T2D)
inferred← citeshttps://doi.org/10.1007/s13300-025-01718-7openalex-snapshot
The Prevalence of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes in Jordan: The PACT-MEA Study
inferred← citeshttps://doi.org/10.1007/s13300-025-01719-6openalex-snapshot
PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s13300-025-01736-5openalex-snapshot
Multicenter, Phase 4 Clinical Study from India to Evaluate the Safety and Efficacy of Insulin Glargine 300 U/ml in Insulin-Naïve People with Type 2 Diabetes Uncontrolled on Oral Anti-hyperglycemic Drugs: SAFEGUARD Study
inferred← citeshttps://doi.org/10.1007/s13340-021-00508-3openalex-snapshot
Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control
inferred← citeshttps://doi.org/10.1007/s13340-021-00560-zopenalex-snapshot
Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth
inferred← citeshttps://doi.org/10.1007/s13340-023-00638-wopenalex-snapshot
Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study
inferred← citeshttps://doi.org/10.1007/s13340-026-00877-7openalex-snapshot
Retrospective real-world database study to examine the prevalence and incidence of cardiovascular diseases and medication prescription in Japanese patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1007/s13410-022-01049-4openalex-snapshot
Evaluation of drug utilization pattern of antidiabetic drugs and 10-year cardiovascular risk in new and recently diagnosed type 2 diabetes mellitus patients: a prospective, longitudinal, observational, hospital-based study
inferred← citeshttps://doi.org/10.1007/s13410-023-01197-1openalex-snapshot
Free T4 is associated with exenatide-related weight loss in patients with type 2 diabetes mellitus and obesity
inferred← citeshttps://doi.org/10.1007/s13410-025-01516-8openalex-snapshot
Signal mining of adverse drug events related to hypovolemia caused by SGLT2 inhibitors based on FAERS database
inferred← citeshttps://doi.org/10.1007/s13410-026-01664-5openalex-snapshot
Evaluating the effect of carbohydrate counting method and standard diabetic diet on glycemic control of children and adolescents with Type 1 Diabetes Mellitus: A randomized controlled trial
inferred← citeshttps://doi.org/10.1007/s13668-026-00773-1openalex-snapshot
Targeting Gut Microbiota by DPP-4 Inhibitors in Obesity: Mechanistic Insights and Therapeutic Implications
inferred← citeshttps://doi.org/10.1007/s13679-021-00444-yopenalex-snapshot
The Most Undertreated Chronic Disease: Addressing Obesity in Primary Care Settings
inferred← citeshttps://doi.org/10.1007/s40200-023-01296-0openalex-snapshot
The diabetic patient between sustainability and effectiveness of new treatments
inferred← citeshttps://doi.org/10.1007/s40200-024-01388-5openalex-snapshot
Individual, interpersonal, and community factors associated with health outcomes in patients with type 2 diabetes mellitus treated at federally qualified health centers
inferred← citeshttps://doi.org/10.1007/s40200-024-01406-6openalex-snapshot
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
inferred← citeshttps://doi.org/10.1007/s40200-024-01412-8openalex-snapshot
Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s40200-025-01795-2openalex-snapshot
Trends and disparities in mortality due to non-insulin dependent diabetes mellitus and acute myocardial infarction: a 23-year analysis from 1999 to 2022
inferred← citeshttps://doi.org/10.1007/s40256-023-00572-xopenalex-snapshot
Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects
inferred← citeshttps://doi.org/10.1007/s40261-023-01255-wopenalex-snapshot
A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China
inferred← citeshttps://doi.org/10.1007/s40262-025-01590-5openalex-snapshot
Factors Accounting for Pharmacodynamic Variability of Basal Insulin Preparations in Euglycemic Clamp Settings in Healthy Individuals
inferred← citeshttps://doi.org/10.1007/s40271-025-00776-0openalex-snapshot
Eliciting Patient-Centric Value Parameters: A National Best-Worst Scaling Profile Case Survey for Second-Line Antidiabetic Drugs in China
inferred← citeshttps://doi.org/10.1007/s40273-023-01268-5openalex-snapshot
A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/s40292-021-00479-1openalex-snapshot
Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis
inferred← citeshttps://doi.org/10.1007/s40618-022-01788-5openalex-snapshot
Erectile dysfunction as a marker of endocrine and glycemic disorders
inferred← citeshttps://doi.org/10.1007/s40618-023-02263-5openalex-snapshot
Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1007/s40619-022-01064-xopenalex-snapshot
Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico
inferred← citeshttps://doi.org/10.1007/s40620-023-01858-8openalex-snapshot
Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data
inferred← citeshttps://doi.org/10.1007/s40670-021-01395-8openalex-snapshot
Integration of Clinical and Scientific Principles in the Teaching of Drug-Drug Interactions
inferred← citeshttps://doi.org/10.1007/s40801-022-00309-3openalex-snapshot
Association Between HbA1c Levels and Diabetic Peripheral Neuropathy: A Case–Control Study of Patients with Type 2 Diabetes Using Claims Data
inferred← citeshttps://doi.org/10.1007/s43440-021-00289-1openalex-snapshot
The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study
inferred← citeshttps://doi.org/10.1007/s43440-021-00347-8openalex-snapshot
Impaired metabolic effects of metformin in men with early-onset androgenic alopecia
inferred← citeshttps://doi.org/10.1007/s43450-023-00460-0openalex-snapshot
Cinnamon Modulates Toll-Like Receptors: a New Therapeutic Approach for Diabetes
inferred← citeshttps://doi.org/10.1016/b978-0-323-85732-1.00055-4openalex-snapshot
NAFLD, the hepatic manifestation of the metabolic syndrome
inferred← citeshttps://doi.org/10.1016/b978-0-323-88426-6.00017-8openalex-snapshot
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
inferred← citeshttps://doi.org/10.1016/b978-0-323-99991-5.00007-3openalex-snapshot
Diabetes: evolution of multifactorial vascular risk reduction
inferred← citeshttps://doi.org/10.1016/bs.apar.2025.08.001openalex-snapshot
Genetically modified helminths as pharmaceutical biofactories
inferred← citeshttps://doi.org/10.1016/j.ajpc.2022.100370openalex-snapshot
County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries
inferred← citeshttps://doi.org/10.1016/j.ajpc.2023.100630openalex-snapshot
Second-year results from CINEMA: A novel, patient-centered, team-based intervention for patients with Type 2 diabetes or prediabetes at high cardiovascular risk
inferred← citeshttps://doi.org/10.1016/j.apnr.2021.151478openalex-snapshot
Factors associated with work ability in adults with diabetes
inferred← citeshttps://doi.org/10.1016/j.arcmed.2021.08.002openalex-snapshot
Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2022.05.010openalex-snapshot
Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits
inferred← citeshttps://doi.org/10.1016/j.autrev.2025.103816openalex-snapshot
The role of CRISPR-Cas9 and CRISPR interference technologies in the treatment of autoimmune diseases
inferred← citeshttps://doi.org/10.1016/j.bbrc.2024.150403openalex-snapshot
Soluble T-cadherin secretion from endothelial cells is regulated via insulin/PI3K/Akt signalling
inferred← citeshttps://doi.org/10.1016/j.bcp.2021.114413openalex-snapshot
Pharmacokinetics of metformin in collagen-induced arthritis rats
inferred← citeshttps://doi.org/10.1016/j.biopha.2021.112393openalex-snapshot
Advances of microneedles in hormone delivery
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115515openalex-snapshot
SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease
inferred← citeshttps://doi.org/10.1016/j.biopha.2024.116631openalex-snapshot
New insights into the roles of Irisin in diabetic cardiomyopathy and vascular diseases
inferred← citeshttps://doi.org/10.1016/j.cardfail.2022.10.426openalex-snapshot
Atherosclerotic Cardiovascular Disease or Heart Failure: First Cardiovascular Event in Adults With Prediabetes and Diabetes
inferred← citeshttps://doi.org/10.1016/j.cca.2023.117516openalex-snapshot
Insulin: Know what your immunoassay detects. Evaluation of two new immunoassays
inferred← citeshttps://doi.org/10.1016/j.cjca.2026.06.027openalex-snapshot
Neighborhood-Level Material Resources and Risk of Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.1016/j.clinthera.2022.04.005openalex-snapshot
Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States
inferred← citeshttps://doi.org/10.1016/j.clinthera.2022.07.009openalex-snapshot
Use of Concurrent Anti-diabetes Medications in Patients With Type 2 Diabetes in Clinical Practice in the United States
inferred← citeshttps://doi.org/10.1016/j.coph.2021.09.001openalex-snapshot
Next-gen therapeutics to spare and expand beta-cell mass
inferred← citeshttps://doi.org/10.1016/j.curtheres.2025.100809openalex-snapshot
Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends
inferred← citeshttps://doi.org/10.1016/j.cyto.2021.155549openalex-snapshot
IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases
inferred← citeshttps://doi.org/10.1016/j.deman.2022.100054openalex-snapshot
Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies
inferred← citeshttps://doi.org/10.1016/j.diabet.2021.101283openalex-snapshot
Glycaemic variabilities: Key questions in pursuit of clarity
inferred← citeshttps://doi.org/10.1016/j.diabet.2021.101285openalex-snapshot
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
showing the first 200 of 968 · page through all 968
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.